Omeros (OMER) Net Margin (2010 - 2026)

Omeros (OMER) reported Net Margin of 48.63% for Q1 2026, down 54.71% sequentially from 107.36% in Q2 2022.

Omeros (OMER) Net Margin (2010 - 2026) Analysis & Trends

Omeros (OMER) has 14 years of Net Margin data on file, last reported at 48.63% in Q1 2026.

For the quarter ending Q1 2026, Net Margin changed N/A year-over-year to 48.63%; the trailing twelve-month figure through Mar 2026 stood at 8.02% (up 4505.0% YoY), and the FY2020 full-year result was 47.51%, down 873.0% from the prior year.
Net Margin retreated to 48.63% in Q1 2026, from 107.36% in the prior quarter.
In the past five years, Net Margin ranged from a high of 107.36% in Q2 2022 to a low of 48.63% in Q1 2026.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	15.02%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	34.53%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	20.17%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	30.33%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Omeros	739.31 Mn	739.31 Mn	9.31 Mn	48.63%

Historic Data

Download Data

Date	Value
Mar 31, 2026	48.63%
Jun 30, 2022	107.36%
Mar 31, 2022	92.67%
Dec 31, 2021	-411.75%
Sep 30, 2021	71.91%
Jun 30, 2021	74.92%
Mar 31, 2021	69.70%
Dec 31, 2020	-899.18%
Sep 30, 2020	-147.29%
Jun 30, 2020	-507.88%
Mar 31, 2020	-125.67%
Dec 31, 2019	-334.80%
Sep 30, 2019	-55.14%
Jun 30, 2019	-228.96%
Mar 31, 2019	-114.05%
Dec 31, 2018	-65.57%
Sep 30, 2018	-3,687.63%
Jun 30, 2018	-6,579.46%
Mar 31, 2018	-1,921.54%
Dec 31, 2017	-178.19%